Exact Sciences CEO Defends Company Against Short-Seller’s Criticism

growth has been modest, which suggests that getting clinicians to not only order Cologuard for the first time, but re-order the test for more patients afterward, will likely remain a focus area for Exact.

Pages: Page 1, Page 2

Author: Jeff Buchanan

Jeff formerly led Xconomy’s Seattle coverage since. Before that, he spent three years as editor of Xconomy Wisconsin, primarily covering software and biotech companies based in the Badger State. A graduate of Vanderbilt, he worked in health IT prior to being bit by the journalism bug.